Author:
Godzenko A. A.,Agafonova E. M.,Dimitreva A. E.,Razumova I. Yu.,Urumova M. M.
Reference29 articles.
1. Sbidian, E., Chaimani, A., Garcia-Doval, I., Do, G., Hua, C., et al., Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis, Cochrane Database Syst. Rev., 2017, vol. 12, no. 12, p. cd011535.
2. Hueber, W., Sands, B.E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., et al., Secukinumab in Crohn’s Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial, Gut, 2012, vol. 61, no. 12, pp. 1693–1700. https://doi.org/10.1136/gutjnl-2011-301668
3. Targan, S.R., Feagan, B., Vermeire, S., Panaccione, R., Melmed, G.Y., Landers, C., Li, D., Russell, Ch., Newmark, R., Zhang, N., Chon, Yu., Hsu, Y.-H., Lin, S.-L., and Klekotka, P., A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn’s disease, Am. J. Gastroenterol., 2016, vol. 111, no. 11, pp. 1599–1607. https://doi.org/10.1038/ajg.2016.298
4. Braun, J., Baraliakos, X., Listing, J., and Sieper, J., Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti–tumor necrosis factor agents infliximab and etanercept, Arthritis Rheum., 2005, vol. 52, no. 8, pp. 2447–2451. https://doi.org/10.1002/art.21197
5. Lindström, U., Olofsson, T., Wedrén, S., Qirjazo, I., and Askling, J., Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study, RMD Open, 2018, vol. 4, no. 2, p. e000762. https://doi.org/10.1136/rmdopen-2018-000762